Advancingmedicine,one volunteerat a time.

A 72-week, randomized, double-blind study evaluating a once-weekly GIP/GLP-1 receptor agonist in adults with obesity or overweight with weight-related comorbidities.

• Adults 18–75 years
• BMI ≥ 30, or ≥ 27 with comorbidity
• No prior bariatric surgery

Evaluating the efficacy and safety of a once-daily oral GLP-1 therapy versus placebo in adults with type 2 diabetes inadequately controlled on metformin.

• Adults 18–70 years
• Diagnosed T2D ≥ 6 months
• HbA1c 7.0–10.5%

A study of an SGLT2 inhibitor combination for slowing kidney function decline in patients with type 2 diabetes and early chronic kidney disease.

• Adults 30–80 years
• T2D with eGFR 30–75
• UACR 200–5000 mg/g

Assessing a novel aldosterone synthase inhibitor in adults whose blood pressure remains uncontrolled despite three or more antihypertensive medications.

• Adults 18–85 years
• Seated SBP ≥ 140 mmHg
• On ≥ 3 BP medications

A randomized, placebo-controlled study of a monthly anti-amyloid monoclonal antibody infusion in participants with mild cognitive impairment or mild dementia due to Alzheimer's.

• Adults 60–85 years
• MMSE score 22–30
• Confirmed amyloid pathology (PET/CSF)

Investigating an oral tau-aggregation inhibitor in cognitively normal adults with elevated brain amyloid, aiming to delay onset of cognitive decline.

• Adults 55–80 years
• Family history of dementia
• No current cognitive impairment

A single-dose immunogenicity and safety study of an mRNA-based respiratory syncytial virus vaccine in adults aged 60 and older.

• Adults ≥ 60 years
• Generally good health
• No RSV vaccination in past 2 years

Evaluating a combined seasonal influenza and COVID-19 mRNA booster vaccine versus separate standard-of-care vaccines in healthy adults.

• Adults 18–64 years
• Prior COVID-19 primary series
• No vaccine in past 90 days

A randomized, placebo-controlled study of a monthly anti-TSLP biologic injection in adults with severe asthma that remains uncontrolled despite high-dose inhaled corticosteroids.

• Adults 18–75 years
• Severe asthma diagnosis ≥ 12 months
• ≥ 2 exacerbations in past year

Evaluating a single-inhaler triple therapy (ICS/LAMA/LABA) versus dual therapy for reducing exacerbations in adults with moderate-to-severe COPD.

• Adults 40–80 years
• Current or former smoker (≥ 10 pack-years)
• Post-bronchodilator FEV1 25–65%

A double-blind study of a novel NMDA-receptor modulator taken with a standard antidepressant in adults with major depressive disorder and inadequate response to prior treatment.

• Adults 18–65 years
• MDD diagnosis (DSM-5)
• Inadequate response to 1–2 antidepressants

Assessing a once-daily SGLT2 inhibitor for reducing cardiovascular death and heart failure hospitalizations in adults with symptomatic HFpEF.

• Adults ≥ 40 years
• NYHA class II–IV symptoms
• LVEF > 40%

A twice-yearly small-interfering RNA injection targeting PCSK9 in adults with elevated LDL cholesterol despite maximally tolerated statin therapy.

• Adults 18–80 years
• LDL-C ≥ 70 mg/dL on statin
• History of ASCVD or high risk